Smoking, obesity, and insulin resistance are well-known risk factors for cancer, yet few epidemiology studies evaluate their role as risk factors for a second primary cancer (SPC).
INTRODUCTION
Continuous advances in cancer treatment have led to a marked improvement in cure rates, and thus an increasedpopulationoflong-termcancersurvivors.
1,2 As a result of both original and treatment-related risk factors, however, survivors are at increased risk for second primary cancers (SPCs), not only at the original site but also at other sites. 3, 4 Although many large populationbased studies demonstrate that smoking, 5, 6 obesity, [7] [8] [9] [10] and insulin resistance [11] [12] [13] are risk factors for first cancers, few studies evaluate the role of known risk factors in the development of SPCs in cancer survivors.
Previously, we conducted a prospective cohort investigation, 5, 6, 14 and during the 7 years of followup, more than 14,900 men were diagnosed with a first cancer. Drawing from that male survivor cohort, we identified the role of the baseline risk factors that existed before the first cancer diagnosis in the development of SPCs.
PATIENTS AND METHODS

Study Population and Data Collection
The National Health Insurance Corporation Study, which enrolled 1,216,041 (901,979 male and 314,062 female) government employees and teachers Ն 20 years old who participated in a national health examination program begun in 1996, includes the results of biennial health examinations and a self-administered questionnaire survey regarding medical history, current health status, family history, tobacco and alcohol consumption, dietary preferences, and leisure-time physical activity. Serum glucose was measured under fasting conditions, and body mass index (BMI) was calculated as kilograms per square meters at enrollment. Data for the incident cancer occurrences were obtained from the Korea Central Cancer Registry. The details of this cohort study, including outcome measures, were reported previously. 5, 6, 14 We restricted our analyses to men because the women generally were younger and the number of female cancer patients was too small for detailed analysis. We retrieved data on 14,944 men with a first cancer. We excluded patients who were dying or diagnosed with multiple primary cancers within the first 30 days of follow-up (n ϭ 763). This left 14,181 patients in the study (Fig 1) .
A cancer was identified as an SPC if it was diagnosed at least 1 month later than the first cancer and was of a different topology, using the four-digit International Classification of Diseases code when available. We observed patients up to December 31, 2002. During the follow-up period of 28,235.22 person-years, we identified 204 SPC occurrences (Fig 1) .
Statistical Methods
The person-years at risk accumulated for each patient beginning with the date of diagnosis of the first primary cancer and ending with the date of diagnosis of an SPC, death, or December 31, 2002, whichever came first. We defined smoking-related cancers as cancers known to have a dose-response relationship with smoking (lung, esophageal, laryngeal, oral, kidney, bladder, pancreas, and liver). 5, 15, 16 We grouped other cancer types and defined them as hepatopancreatobiliary (liver, pancreas, or gallbladder) cancer 17, 18 or genitourinary (kidney, bladder, or prostate) cancer. 19 To compare cancer incidence between the general population and the cancer survivors, we calculated the age-standardized incidence rate by a direct method. We used the standard Poisson regression model to estimate the relative risk (RR) for development of an SPC in relation to smoking history, obesity, and insulin resistance before the first primary tumor. For multivariate analyses, we used the following categories: smoking status (current, former, or never smoker), BMI (Ͻ 23, 23 to 24.9, Ն 25 kg/m 2 ), 20 fasting serum glucose level in (Ͻ 110, 110-125, Ն 126 mg/dL), 21 leisure-time physical activity (low, Ͻ two times/wk for Ͻ 30 minutes each time; moderate, two to four times/wk for Ն 30 minutes each time or Ն five times/wk for Ͻ 30 minutes each time; high, Ն five times/wk for Ն 30 minutes each time), and alcohol consumption (0, 1 to 124.1, or Ն 124.2 g/wk). For some analyses, we combined those categories into a single stratum because of small numbers of SPC occurrences. We estimated RR and 95% CIs after adjusting for age or other variables. All statistical tests were two sided and performed with SAS Statistical Package version 8.1 (SAS Institute Inc, Cary, NC). We considered P Ͻ .05 statistically significant.
RESULTS
The mean age of the 14,181 patients was 50.8 years. Table 1 lists the baseline characteristics. The mean duration of follow-up was 2.0 years, during which we observed 204 occurrences of SPC. There were 5,653 deaths among the patients who did not have an SPC (Fig 1) , most of which were due to cancer. Only 23 (11.3%) of the SPCs occurred at the same site as the first cancer. Table 2 lists the number of occurrences and the age-standardized incidence rate of first primary cancers and SPCs. The overall agestandardized incidence SPC rate was 603.2 occurrences per 100,000 person-years, which was about 2.3 times higher than that of first primary cancers (259.9 occurrences per 100,000 person-years). For every site except the stomach, the age-standardized incidence rate was higher in cancer survivors than in the general population. Among those with an unfavorable risk factor such as smoking or obesity, the overall age-standardized cancer incidence rates for SPCs were more than twice those for first primary cancers. In smokers, the age-standardized incidence rates of head and neck, colorectal, lung, hepatopancreatobiliary, genitourinary, and smoking-related cancers were higher in the survivors than in the general population. In men with a BMI Ն 25 kg/m 2 , the age-standardized incidence rate of colorectal and genitourinary cancers was about 5 times higher for second than for first primary cancers. Because of the small number of SPC occurrences in cancer survivors with fasting serum glucose levels Ն 126 mg/dL (n ϭ 22), we could not compare the age-standardized cancer incidence rate for each site, but the rate for all cancers was 1.6 times higher for SPCs (856.6 occurrences per 100,000 personyears) than for first primary cancers (544.4 occurrences per 100,000 person-years). Table 3 lists the estimated RR of SPCs and the 95% CIs by age at diagnosis. Survivors whose first cancer was diagnosed at Ն 60 years old had an 80% increase in risk for all types of cancer compared with those who were first diagnosed at younger than 50 years old, even after statistical control of confounding factors. The relationship between age at first cancer diagnosis and SPC was statistically significant for head and neck (RR, 3.38; 95% CI, 1.01 to 11.32), stomach (RR, 4.47; 95% CI, 1.44 to 13.84), lung (RR, 4.03; 95% CI, 1.26 to 12.93), and smoking-related cancers (RR, 2.24; 95% CI, 1.17 to 4.30).
Age-Standardized Incidence Rates of First Primary Cancers and SPCs
Age at First Primary Cancer and Risk of SPC
Prediagnosis Smoking and SPC
Age-and multivariate-adjusted analyses showed a significant relationship between smoking status before the first cancer diagnosis and SPC incidence for lung and smoking-related cancers (Table 4) .
Second primary lung cancers were not found in survivors who had never smoked. Furthermore, second primary lung cancers were more likely to develop in current smokers than in former smokers (RR, 3.69; 95% CI, 1.35 to 10.09). As in smoking-related cancer incidence, we observed positive linear trends with smoking status in age-adjusted analysis (P Ͻ .01). The effect persisted in multivariate analysis, with current smokers having a higher RR for smoking-related SPCs (RR, 2.02; 95% CI, 1.02 to 4.03) than those who had never smoked.
Prediagnosis BMI and SPC
Compared with the reference category (BMI Ͻ 23 kg/m 2 ), survivors with a prediagnosis BMI Ն 25 kg/m 2 had a significantly elevated RR for colorectal SPC (RR, 3.45; 95% CI, 1.50 to 7.93) with dosedependent relationships in multivariate analysis (Table 5 ). We also found that patients with BMI Ն 25 kg/m 2 had a higher RR for genitourinary SPC (RR, 3.61; 95% CI, 1.36 to 9.54) than those with BMI less than 25 kg/m 2 (Table 5 ). When we stratified the patients based on smoking history, the survivors with prediagnosis obesity had a significant high risk of second primary colorectal cancer in both current smokers (RR, 3.17; 95% CI, 1.06 to 9.51) and former/nonsmokers (RR, 3.90; 95% CI, 1.07 to 14.21).
Prediagnosis Fasting Serum Glucose Level and SPC
After adjusting for patient age, we observed positive linear trends for the relationship between prediagnosis fasting serum glucose levels and hepatopancreatobiliary or smoking-related SPCs (Table 6 ). These effects persisted in multivariate analysis, with persons with the highest fasting serum glucose level (Ն 126 mg/dL) having a higher RR for hepatopancreatobiliary (3.33; 95% CI, 1.33 to 8.37) and smokingrelated (1.93; 95% CI, 1.01 to 3.68) SPCs.
When we repeated Poisson regression analysis with different time frames of SPC, such as 3 or 6 months, the impact of prediagnosis smoking history and obesity on SPC risk was similar to those with a 1-month time frame. Only the association between insulin resistance and SPCs was attenuated and not statistically significant in different time frames (data not shown).
DISCUSSION
In this large population-based cohort study, we found that among male cancer survivors, prediagnosis risk factors (a history of smoking, obesity, and elevated fasting serum glucose levels) were independent risk factors for several SPCs after adjusting for confounders such as physical activity, alcohol consumption, and age at first cancer diagnosis. The overall age-standardized incidence rate was 2.3 times higher for an SPC than for a first cancer in the general male population. When we compared the age-standardized cancer incidence rates for male cancer survivors and the general male population, we found similar results for most cancer sites except the stomach. We also found that in smokers, the age-standardized incidence rate of smoking-related cancers was higher in the survivors than in the general population. A previous study showed that the risk of a smoking-related SPC after laryngeal cancer was elevated; although laryngeal cancer is usually smoking-related, data on smoking were not given. 22 Little is known about the incidence of secondary nonsmoking-related cancers in smokers. In this study, we found that in smokers, the age-standardized incidence rate was about 5 times higher for second than for first primary colorectal cancers. The age-standardized incidence rate was also higher for second than for first primary cancers in several sites among those with a different unfavorable risk factor, such as obesity or insulin resistance.
We also showed positive linear trends in SPC incidence with increasing age at first cancer diagnosis for head and neck, stomach, lung, and smoking-related cancers, and all cancer combined. Although advancing age is known to be associated with an increased risk of a first cancer in the general population, 23 the relationship between age at first cancer diagnosis and the risk of an SPC is controversial. [24] [25] [26] Our results suggest that physicians should monitor not only for recurrence of a first cancer, but also for new primary cancers, especially in the elderly.
Our finding that prediagnosis smoking was an independent risk factor for secondary lung and other smoking-related cancers is consistent with other studies suggesting that smoking increases the risk of SPCs, especially lung cancers.
27,28 Current smokers who have a nonrespiratory cancer are also at increased risk for SPCs. In Japan, smoking significantly increases the risk for SPC in esophageal 25 and gastric cancer 29 patients. In aerodigestive cancers, a history of smoking, particularly heavy smoking, is a universally recognized risk factor for SPCs, 30-32 and prediagnosis smoking is an independent poor prognostic factor in cancer patients.
14 Together with previous findings, our results suggest that groups with a high cancer risk need to be educated continually not to smoke-not only to prevent a first cancer, but also to prevent a second cancer. We also found significant dose-dependent relationships between prediagnosis BMI and the risk of colorectal and genitourinary SPCs, as has been reported for first cancers.
7-10 Although few prospective studies have investigated the association between SPCs and obesity, some studies have shown obesity to be a risk factor for recurrent colorectal, prostate, or breast cancer. [33] [34] [35] Those studies, however, did not consider the SPCs in discordant sites. Only one case-control study showed obesity to be a risk factor for colorectal cancer in breast cancer patients. 36 In our study, the proportion of concordant SPCs was 11.3%, confirming that obesity is a risk factor for several SPCs at discordant as well as concordant sites.
Smoking and other confounding risk factors for SPC may distort the link between BMI and SPC risk. Smoking is associated inversely with body weight, 37, 38 and that must be considered when examining the effect of BMI on SPC risk. In our study, the associations between obesity and the risk of second primary colorectal cancer were statistically significant in both current smokers and former/nonsmokers.
The mechanisms underlying the association between obesity and cancer are still uncertain. Individuals in the obese population are known to have increased blood levels of sex steroids, insulin, insulinlike growth factor (IGF), leptin, and adipocytokine, and these could influence cancer development or growth. 10,39 Recent studies had revealed that weight gain after the diagnosis of some cancers is a common occurrence, and the prevalence of elevated BMIs is high.
39,40
Because excess weight could increase the risk of several SPCs, clinician involvement to reduce the impact of excess weight in cancer patients will continue to be important.
Glucose intolerance is another risk factor for cancer, both overall and for particular sites, [11] [12] [13] but few prospective studies have identified its relationship to SPC risk. One study showed that colon cancer patients with diabetes experience a significantly elevated recurrence rate. 41 Another showed that an elevated IGF level is a risk factor for second primary head and neck cancers. 42 We found no studies, however, that considered the effects of other important risk factors, such as BMI, exercise, and alcohol consumption. In the National Health Insurance Corporation Study, we found that the increased SPC risk associated with high serum glucose was unchanged when adjusted for BMI and other known risk factors. To our knowledge, this is the first study to demonstrate positive linear trends in SPC incidence with increasing fasting serum glucose levels for hepatopancreatobiliary and smoking-related cancers. The multicancer effect is consistent with postulated mechanisms of systemic consequences of hyperinsulinemia. [11] [12] [13] 43 Given that IGF-1 and insulin receptors are overexpressed in cancer cells, high insulin levels could lead to a selective growth advantage. [11] [12] [13] 43 IGF-1 has been shown to be an important regulator of angiogenesis, and it could increase vascular endothelial growth factor production in cancer cells. 44, 45 In addition, insulin resistance is associated with the elevation in proinflammatory markers such as C-reactive protein, interleukin-6, and tumor necrosis factor ␣, 46,47 and inflammation is a potential contributory factor in the development of several cancers. [48] [49] [50] Additional study on the association between inflammatory markers and SPC risk is needed.
The strengths of this study include its prospective, populationbased design, reliable assessment of cancer incidence, and detailed assessment of the health risk factors that preceded the first cancer diagnosis. Many other population-based cohort studies, in contrast, rely on national linkage registries that do not have this type of information, thereby limiting the ability to adjust for potential confounders. 3, 51 In addition, most studies that identify SPC risk factors collect health behavior information after the diagnosis, 30,38 and those data may not accurately represent long-term exposure because body weight and behaviors such as smoking, alcohol consumption, and exercise are influenced by the experience of cancer.
52,53 Some studies do collect information about health behaviors that preceded the cancer diagnosis at the time of patient enrollment, 25, 29 but those are subject to recall bias. Another advantage of our study is that height and weight measurements were made by trained personnel. This is preferable to self-reported data (which have been used frequently in largescale cohort studies) because heavier individuals tend to under-report their weight. 54 Our study has several limitations. First, our sample might not represent cancer patients in the general population because cancer registration is not yet complete throughout Korea, although it includes approximately 90% of patients, 55 and the patients held stable, secure jobs. This population, however, was relatively easy to observe and offered a relatively reliable source of information. Second, because we did not include information about first cancer treatment, we could not consider its effect. The carcinogenic effects of cancer-related treatment, however, are usually delayed, 3 and the follow-up period of our study was relatively short (mean, 2.0 years). Third, our adjustment for the small number of SPC occurrences by combining some risk factor categories into a single stratum could have masked real associations between prediagnosis environmental factors and SPC risk. Despite this technique, however, we found statistically meaningful associations between smoking history and lung cancer and between obesity and genitourinary cancer. Fourth, although we excluded individuals whose follow-up was less than 1 month (the same time frame used in other SPC studies 3, 56 ) to avoid uncertainty as to which was the first cancer, there were some chances of an SPC misclassification bias. However, when we compared analyses with different time frames, such as 3 or 6 months, the results were similar to those with a 1-month time frame.
Our study showed that male cancer survivors had a higher primary cancer incidence than the general male population. We also showed that prediagnosis smoking, obesity, and elevated fasting serum glucose levels, which are well-known risk factors for cancer in the general population, seemed to increase the risk of several SPCs. Our findings suggest that more thorough surveillance and screening for SPCs is needed for cancer survivors, especially those patients with these risk factors. Additional study is needed to examine whether discontinuing smoking and reducing weight or insulin resistance might decrease the incidence of SPCs.
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